Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1575-1587

  Dalvie, Deepak ^a   Sun, Hao ^a   Xiang, Cathie ^a   Hu, Qiyue ^a   Jiang, Ying ^a   Kang, Ping ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOZONIPORIDE; ALDEHYDE OXIDASE; ALKYL GROUP; CYCLOPROPANE DERIVATIVE; GUANIDINE; QUINOLONE; UNCLASSIFIED DRUG; ZONIPORIDE; ZONIPORIDE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; CHEMICAL BOND; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ELECTROPHILICITY; ENERGY TRANSFER; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; MOLECULAR INTERACTION; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN MOTIF; STATIC ELECTRICITY; STRUCTURAL HOMOLOGY; STRUCTURE METABOLISM RELATIONSHIP;

ALDEHYDE OXIDASE; BIOCATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GUANIDINES; HALF-LIFE; KINETICS; MODELS, MOLECULAR; OXIDATION-REDUCTION; PYRAZOLES;

EID: 84863954854     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045823     Document Type: Article

References (42)

1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, et al. (1996) Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26:1035-1055.
2. Afzelius L, Arnby CH, Broo A, Carlsson L, Isaksson C, Jurva U, Kjellander B, Kolmodin K, Nilsson K, Raubacher F, et al. (2007) State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. Drug Metab Rev 39:61-86.
3. Al-Salmy HS (2001) Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 51:249-253.
4. Becke AD (1988) Density-functional exchange-energy approximation with correct asymptotic behavior. Phys Rev A 38:3098-3100.
5. Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16:119-156.
6. Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85-127.
7. Beedham C, Bruce SE, Critchley DJ, and Rance DJ (1990) 1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochem Pharmacol 39:1213-1221.
8. Chan K, Poon R, and O'Brien PJ (2008) Application of structure-activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of α,β-unsaturated aldehydes. J Appl Toxicol 28:1027-1039.
9. Cronin MT, Manga N, Seward JR, Sinks GD, and Schultz TW (2001) Parametrization of electrophilicity for the prediction of the toxicity of aromatic compounds. Chem Res Toxicol 14:1498-1505.
10. Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641-654.
11. Dastmalchi S and Hamzeh-Mivehrod M (2005) Molecular modelling of human aldehyde oxidase and the identification of the key interactions in the enzyme-substrate complex. DARU-J Fac Pharm 13:82-93.
12. de Groot MJ (2006) Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 11:601-606.
13. Garattini E and Terao M (2011) Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 43:374-386.
14. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
15. Ghafourian T and Rashidi MR (2001) Quantitative study of the structural requirements of phthalazine/quinazoline derivatives for interaction with human liver aldehyde oxidase. Chem Pharm Bull (Tokyo) 49:1066-1071.
16. Guzman-Perez A, Wester RT, Allen MC, Brown JA, Buchholz AR, Cook ER, Day WW, Hamanaka ES, Kennedy SP, Knight DR, et al. (2001) Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett 11:803-807.
17. Hall WW and Krenitsky TA (1986) Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs. Arch Biochem Biophys 251:36-46.
18. Hille R (2005) Molybdenum-containing hydroxylases. Arch Biochem Biophys 433:107-116.
19. Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, et al. (2011) Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett 21:5939-5943.
20. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, and Watabe T (1999) Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-428.
21. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
22. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, Marala RB, Wester RT, Guzman-Perez A, Hill RJ, et al. (2001) A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther 297:254-259.
23. Krenitsky TA, Neil SM, Elion GB, and Hitchings GH (1972) A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 150:585-599.
24. Lewis DF, Jacobs MN, and Dickins M (2004) Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9:530-537.
25. Linton A, Kang P, Ornelas M, Kephart S, Hu Q, Pairish M, Jiang Y, and Guo C (2011) Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO). J Med Chem 54:7705-7712.
26. Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, et al. (2009) Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem 52:7446-7457.
27. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
28. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
29. Pryde DC, Tran TD, Jones P, Duckworth J, Howard M, Gardner I, Hyland R, Webster R, Wenham T, Bagal S, et al. (2012) Medicinal chemistry approaches to avoid aldehyde oxidase metabolism. Bioorg Med Chem Lett 22:2856-2860.
30. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813.
31. Schofield PC, Robertson IG, and Paxton JW (2000) Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl]acridine-4- carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol 59:161-165.
32. Sharma R, Eng H, Walker GS, Barreiro G, Stepan AF, McClure KF, Wolford A, Bonin PD, Cornelius P, and Kalgutkar AS (2011) Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol 24:2207-2216.
33. Smith DA (2011) Discovery and ADMET: where are we now. Curr Top Med Chem 11:467-481.
34. Sun H, Bessire AJ, and Vaz A (2012) Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism. Bioorg Med Chem Lett 22:371-376.
35. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, and Yost GS (2009) Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1- indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos 37:672-684.
36. Sun H and Scott DO (2010) Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 75:3-17.
37. Sun H and Scott DO (2011) Metabolism of 4-aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design. ACS Med Chem Lett 2:638-643.
38. Torres RA, Korzekwa KR, McMasters DR, Fandozzi CM, and Jones JP (2007) Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. J Med Chem 50:4642-4647.
39. Tracey WR, Allen MC, Frazier DE, Fossa AA, Johnson CG, Marala RB, Knight DR, and Guzman-Perez A (2003) Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev 21:17-32.
40. Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, et al. (2011) Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorg Med Chem Lett 21:2389-2393.
41. van de Waterbeemd H, Smith DA, and Jones BC (2001) Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 15:273-286.
42. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.